Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Current Liabilities (2017 - 2025)

Arcus Biosciences (RCUS) has 8 years of Total Current Liabilities data on record, last reported at $235.0 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities changed N/A year-over-year to $235.0 million; the TTM value through Sep 2025 reached $235.0 million, changed N/A, while the annual FY2023 figure was $184.0 million, 4.66% down from the prior year.
  • Total Current Liabilities reached $235.0 million in Q3 2025 per RCUS's latest filing, up from $210.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $235.0 million in Q3 2025 and bottomed at $130.4 million in Q2 2021.
  • Average Total Current Liabilities over 4 years is $173.4 million, with a median of $177.2 million recorded in 2022.
  • The widest YoY moves for Total Current Liabilities: up 528.71% in 2021, down 12.28% in 2021.
  • A 4-year view of Total Current Liabilities shows it stood at $166.0 million in 2021, then grew by 16.27% to $193.0 million in 2022, then fell by 4.66% to $184.0 million in 2023, then increased by 27.72% to $235.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $235.0 million in Q3 2025, $210.0 million in Q2 2025, and $184.0 million in Q4 2023.